FOLD Debt-to-Equity Ratio Analysis

Amicus Therapeutics currently has a Debt-to-Equity Ratio of 1.43x, meaning for every dollar of shareholder equity, the company carries $1.43 in debt—a common measure of financial leverage.

This is well above the healthcare sector median of 0.43x and places the company at the 86th percentile among peers, indicating substantially higher reliance on borrowed funds. The year-over-year change is not available, but the ratio dropped 18.8% quarter-over-quarter from 1.76x to 1.43x, showing a recent reduction in debt relative to equity. While the absolute level remains elevated and suggests elevated financial risk, the declining trend points to a gradual deleveraging that may reduce that risk over time. The combination of a high current ratio and a downward trend creates a mixed picture—the leverage is still a concern, but the improvement offers some offset. This metric supports the overall NEUTRAL verdict, as it neither confirms a clear strength nor flags an imminent danger, balancing a high starting point with recent progress.

Frequently Asked Questions

Closest Sector Peers